Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis
João Marcos de Azevedo Delou,1–3 Giselle Maria Vignal,4 Vanessa Índio-do-Brasil,2,5 Maria Theresa de Souza Accioly,4 Taiana Sousa Lopes da Silva,2 Diogo Nascimento Piranda,2,3 Marcelo Sobral-Leite,2,6 Marcelo Alex de Carvalho,2,7 Márcia Alves Marques Capell...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/faf8a0e4faea49f5a4e0682c4f76ea51 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:faf8a0e4faea49f5a4e0682c4f76ea51 |
|---|---|
| record_format |
dspace |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Breast Cancer ABCB1 Single Nucleotide Polymorphisms Immunohistochemistry Disease-Free Survival. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
Breast Cancer ABCB1 Single Nucleotide Polymorphisms Immunohistochemistry Disease-Free Survival. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Delou JM Vignal GM Índio-do-Brasil V Accioly MT da Silva TS Piranda DN Sobral-Leite M Carvalho MA Capella MA Vianna-Jorge R Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| description |
João Marcos de Azevedo Delou,1–3 Giselle Maria Vignal,4 Vanessa Índio-do-Brasil,2,5 Maria Theresa de Souza Accioly,4 Taiana Sousa Lopes da Silva,2 Diogo Nascimento Piranda,2,3 Marcelo Sobral-Leite,2,6 Marcelo Alex de Carvalho,2,7 Márcia Alves Marques Capella,1,8 Rosane Vianna-Jorge2,3,5 1Programa de Bioquímica e Biologia Celular, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, 2Programa de Farmacologia, Coordenação de Pesquisa, Instituto Nacional de Câncer, 3Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 4Divisão de Patologia, Instituto Nacional de Câncer, 5Escola Nacional de Saúde Pública – FIOCRUZ, Rio de Janeiro, Brazil; 6Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 7Instituto Federal do Rio de Janeiro, 8Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Abstract: ABCB1 gene encodes an adenosine 5’-triphosphate–binding cassette transporter, which not only confers multidrug resistance phenotype in malignant cells, but is also present in several nonmalignant tissues. For the last thirty years, ABCB1 expression in breast cancer has been described by many authors, but the extent of expression differs among the studies, and there is no consensus regarding its potential role in carcinogenesis or in the tumor response to antineoplastic drugs. This study aimed to characterize the expression of ABCB1 in breast tumors as a function of genetic, clinical, and histopathological variables. The ABCB1 expression was also evaluated in nonmalignant mammary tissues adjacent to tumors and in benign lesions. The detection of ABCB1 protein was performed by immunohistochemistry in tissue specimens of excised breasts obtained from a prospective cohort of Brazilian women with breast cancer. The association of ABCB1 protein levels with ABCB1 mRNA, gene polymorphisms, and clinical and histopathological variables was also evaluated. The Kaplan–Meier curves and multivariate Cox regression analyses were conducted to identify independent predictors of disease-free survival of patients with breast cancer. ABCB1 was detected in 86.3% (656) of breast tumors, 98.8% (606) of nonmalignant mammary tissue adjacent to tumors, and 100% (28) of benign lesions. Reduced ABCB1 protein levels in breast tumors was associated with triple-negative subtype (adjusted odds ratio [ORadj] =0.24; 95% confidence interval [CI] =0.13–0.45), lymph node status < pN2 (ORadj =0.27; 95% CI =0.10–0.71), tumor size >2 cm (ORadj =0.55; 95% CI =0.32–0.93), and hypertensive status (ORadj =0.42; 95% CI =0.24–0.73), and it was significantly associated with shorter disease-free survival, either for all breast cancer patients (p log-rank =0.012; hazard ratio [HR] =3.46; 95% CI =1.21–9.91) or for those with triple-negative tumors (p log-rank =0.007; HR =11.41; 95% CI =1.29–100.67). The loss of constitutive ABCB1 expression in breast cancer, especially in triple-negative tumors, seems to indicate a subgroup of worse prognosis. Keywords: multidrug resistance, single-nucleotide polymorphisms, immunohistochemistry, disease-free survival, triple-negative breast cancer, hypertension |
| format |
article |
| author |
Delou JM Vignal GM Índio-do-Brasil V Accioly MT da Silva TS Piranda DN Sobral-Leite M Carvalho MA Capella MA Vianna-Jorge R |
| author_facet |
Delou JM Vignal GM Índio-do-Brasil V Accioly MT da Silva TS Piranda DN Sobral-Leite M Carvalho MA Capella MA Vianna-Jorge R |
| author_sort |
Delou JM |
| title |
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| title_short |
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| title_full |
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| title_fullStr |
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| title_full_unstemmed |
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis |
| title_sort |
loss of constitutive abcb1 expression in breast cancer associated with worse prognosis |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/faf8a0e4faea49f5a4e0682c4f76ea51 |
| work_keys_str_mv |
AT deloujm lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT vignalgm lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT indiodobrasilv lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT acciolymt lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT dasilvats lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT pirandadn lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT sobralleitem lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT carvalhoma lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT capellama lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis AT viannajorger lossofconstitutiveabcb1expressioninbreastcancerassociatedwithworseprognosis |
| _version_ |
1718402507253743616 |
| spelling |
oai:doaj.org-article:faf8a0e4faea49f5a4e0682c4f76ea512021-12-02T02:28:28ZLoss of constitutive ABCB1 expression in breast cancer associated with worse prognosis1179-1314https://doaj.org/article/faf8a0e4faea49f5a4e0682c4f76ea512017-06-01T00:00:00Zhttps://www.dovepress.com/loss-of-constitutive-abcb1-expression-in-breast-cancer-associated-with-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314João Marcos de Azevedo Delou,1–3 Giselle Maria Vignal,4 Vanessa Índio-do-Brasil,2,5 Maria Theresa de Souza Accioly,4 Taiana Sousa Lopes da Silva,2 Diogo Nascimento Piranda,2,3 Marcelo Sobral-Leite,2,6 Marcelo Alex de Carvalho,2,7 Márcia Alves Marques Capella,1,8 Rosane Vianna-Jorge2,3,5 1Programa de Bioquímica e Biologia Celular, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, 2Programa de Farmacologia, Coordenação de Pesquisa, Instituto Nacional de Câncer, 3Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, 4Divisão de Patologia, Instituto Nacional de Câncer, 5Escola Nacional de Saúde Pública – FIOCRUZ, Rio de Janeiro, Brazil; 6Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 7Instituto Federal do Rio de Janeiro, 8Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil Abstract: ABCB1 gene encodes an adenosine 5’-triphosphate–binding cassette transporter, which not only confers multidrug resistance phenotype in malignant cells, but is also present in several nonmalignant tissues. For the last thirty years, ABCB1 expression in breast cancer has been described by many authors, but the extent of expression differs among the studies, and there is no consensus regarding its potential role in carcinogenesis or in the tumor response to antineoplastic drugs. This study aimed to characterize the expression of ABCB1 in breast tumors as a function of genetic, clinical, and histopathological variables. The ABCB1 expression was also evaluated in nonmalignant mammary tissues adjacent to tumors and in benign lesions. The detection of ABCB1 protein was performed by immunohistochemistry in tissue specimens of excised breasts obtained from a prospective cohort of Brazilian women with breast cancer. The association of ABCB1 protein levels with ABCB1 mRNA, gene polymorphisms, and clinical and histopathological variables was also evaluated. The Kaplan–Meier curves and multivariate Cox regression analyses were conducted to identify independent predictors of disease-free survival of patients with breast cancer. ABCB1 was detected in 86.3% (656) of breast tumors, 98.8% (606) of nonmalignant mammary tissue adjacent to tumors, and 100% (28) of benign lesions. Reduced ABCB1 protein levels in breast tumors was associated with triple-negative subtype (adjusted odds ratio [ORadj] =0.24; 95% confidence interval [CI] =0.13–0.45), lymph node status < pN2 (ORadj =0.27; 95% CI =0.10–0.71), tumor size >2 cm (ORadj =0.55; 95% CI =0.32–0.93), and hypertensive status (ORadj =0.42; 95% CI =0.24–0.73), and it was significantly associated with shorter disease-free survival, either for all breast cancer patients (p log-rank =0.012; hazard ratio [HR] =3.46; 95% CI =1.21–9.91) or for those with triple-negative tumors (p log-rank =0.007; HR =11.41; 95% CI =1.29–100.67). The loss of constitutive ABCB1 expression in breast cancer, especially in triple-negative tumors, seems to indicate a subgroup of worse prognosis. Keywords: multidrug resistance, single-nucleotide polymorphisms, immunohistochemistry, disease-free survival, triple-negative breast cancer, hypertensionDelou JMVignal GMÍndio-do-Brasil VAccioly MTda Silva TSPiranda DNSobral-Leite MCarvalho MACapella MAVianna-Jorge RDove Medical PressarticleBreast CancerABCB1Single Nucleotide PolymorphismsImmunohistochemistryDisease-Free Survival.Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol Volume 9, Pp 415-428 (2017) |